痛风患者起始别嘌醇治疗的用药依从性:临床实践研究数据链(CPRD)的回顾性队列研究
该研究基于英国临床实践研究数据链(1987—2014年),纳入年龄≥40岁、新诊断痛风并开始服用别嘌醇的患者48 280例,分析其停药(首次用药间隔≥90天)与不依从(覆盖天数比例<80%)情况及相关因素。结果显示,起始别嘌醇后1年停药比例为38.5%,5年升至56.9%,首次90天间隔的中位时间为1029天,61%的患者不依从;女性、当前吸烟者风险升高,高龄、超重、合并症及使用抗高血压药或秋水仙碱者风险降低。
要点
- 起始别嘌醇后1年停药38.5%,5年升至56.9%。
- 首次90天用药间隔的中位时间为1029天,61%的患者不依从。
- 首次间隔后1年内仅43.3%重启治疗,其中仅52.3%坚持1年。
核心结论
- 痛风患者起始别嘌醇治疗的用药依从性差,女性和较年轻患者及合并症较少的患者尤其如此;首次中断后重新开始治疗者依从性仍低。
研究设计与样本
- 英国临床实践研究数据链(1987—2014年)回顾性数据分析,纳入年龄≥40岁的新诊断痛风并开始服用别嘌醇的患者48 280例。
- 采用Kaplan-Meier统计估算起始别嘌醇者及首次中断后重启治疗者首次90天用药间隔的比例与中位时间,并计算全程覆盖天数比例<80%的不依从比例。
- 采用多变量Cox回归或logistic回归分别评估与停药或不依从相关的因素。
主要发现
- 起始别嘌醇后停药比例由1年的38.5%(95%CI:38.1,38.9)升至5年的56.9%(95%CI:56.4,57.4)。
- 首次90天用药间隔的中位时间为1029天(95%CI:988,1078),全程不依从(覆盖天数比例<80%)比例为61%。
- 首次用药间隔后1年内重启治疗者为43.3%(95%CI:42.7,43.9),其中仅52.3%(95%CI:51.4,53.1)坚持治疗1年。
- 女性及当前吸烟者停药和不依从风险升高;年龄较大、超重、使用抗高血压药物或秋水仙碱、患有痴呆、糖尿病或血脂异常者风险降低。
关键数值与推荐
- 停药定义为首次用药间隔≥90天;不依从定义为全程覆盖天数比例<80%。
- 起始别嘌醇后1年停药38.5%(95%CI:38.1,38.9),5年停药56.9%(95%CI:56.4,57.4)。
- 首次90天用药间隔的中位时间1029天(95%CI:988,1078);全程不依从比例61%。
- 首次间隔后1年内重启治疗43.3%(95%CI:42.7,43.9),重启者中坚持1年者52.3%(95%CI:51.4,53.1)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: When urate lowering therapy is indicated in patients with gout, medication adherence is essential. This study assesses non-persistence and non-adherence in patients with newly diagnosed gout, and identifies factors associated with poor medication adherence. METHODS: A retrospective data analysis was performed within the UK Clinical Practice Research Datalink (1987-2014) among incident gout patients, aged ⩾40 years and starting allopurinol (n = 48 280). The proportion of patients non-persistent (a first medication gap of ⩾90 days) after 1 and 5 years, and median time until a first 90-day gap was estimated using Kaplan-Meier statistics in those starting allopurinol and restarting after a first interruption. Non-adherence (proportion of days covered <80%) over the full observation period was calculated. Multivariable Cox- or logistic regressions assessed factors associated with non-persistence or non-adherence, respectively. RESULTS: Non-persistence increased from 38.5% (95% CI: 38.1, 38.9) to 56.9% (95% CI: 56.4, 57.4) after 1 and 5 years of initiation. Median time until a first 90-day gap was 1029 days (95% CI: 988, 1078) and 61% were non-adherent. After a first gap, 43.3% (95% CI: 42.7, 43.9) restarted therapy within 1 year, yet only 52.3% (95% CI: 51.4, 53.1) persisted for 1 year. Being female and a current smoker increased the risk for non-persistence and non-adherence, while older age, overweight, receiving anti-hypertensive medication or colchicine and suffering from dementia, diabetes or dyslipidaemia decreased the risk. CONCLUSION: Medication adherence among gout patients starting allopurinol is poor, particularly among females and younger patients and patients with fewer comorbidities. Medication adherence remains low in those reinitiating after a first gap.
引用
- Scheepers LEJM, Burden AM, Arts ICW, et al. Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD). Rheumatology (Oxford). 2018. PMID: 29893941. doi:10.1093/rheumatology/key155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。